NPCE IGE FDA approval could enable growth, commercialization by 2027
Drug-resistant epilepsy is cited as under-penetrated. Initiatives and expanded indications like IGE are expected to drive adoption, with potential FDA approval for IGE in 2027 and a subsequent commercialization ramp.